
News|Articles|December 1, 2023
AAO 2023: Luminopia, first FDA-approved digital therapeutic for amblyopia
Author(s)David Hutton, Sheryl Stevenson
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Advertisement
Rupa Wong, MD, spoke with the Ophthalmology Times team about Luminopia, the first FDA-approved digital therapeutic for amblyopia at this year's American Academy of Ophthalmology meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix randomizes first patient in HELIOS-3
2
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
3
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care
4
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
5


















































.png)


